5-Amino-1MQ
NNMT Inhibitor — Metabolic Epigenetics
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme highly expressed in fat tissue that consumes SAM (S-adenosylmethionine) and produces methylnicotinamide. By blocking NNMT, 5-Amino-1MQ increases NAD+ precursor availability, alters adipocyte epigenetics, and appears to reverse fat cell programming.
At a Glance
NNMT is overexpressed in obese adipose tissue and acts as a metabolic brake — consuming NAD+ precursors and adding epigenetic methyl groups that lock fat cells in an energy-storing state. Inhibiting NNMT removes this brake, shifting adipocyte gene expression toward fat burning.
Preclinical data from Cornell and Weill Cornell Medicine shows 5-Amino-1MQ prevents fat accumulation in high-fat-diet mouse models without food intake reduction — suggesting a mechanism acting on adipocyte metabolism directly rather than through appetite suppression.
The NAD+ precursor connection is significant — NNMT inhibition increases available methylation substrates and may synergize with direct NAD+ supplementation by preserving the substrate pool NNMT normally depletes.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
NNMT Enzyme Inhibition
Blocks nicotinamide N-methyltransferase — preventing SAM consumption and methylnicotinamide production in adipose tissue.
NAD+ Precursor Preservation
NNMT inhibition increases available NAD+ precursors (nicotinamide) by blocking their methylation and degradation — synergizing with direct NAD+ supplementation.
Adipocyte Epigenetic Reprogramming
Alters the methylation state of fat cell chromatin, shifting gene expression patterns from energy-storing to energy-expending phenotype.
Fat Oxidation Without Appetite Suppression
Preclinical data shows fat mass reduction without reduced food intake — a purely metabolic rather than appetite-based mechanism.
- Fat accumulation prevention — high-fat diet models without caloric restriction
- Adipocyte epigenetic reprogramming — NNMT's role in fat cell gene expression
- NAD+ pathway interactions — NNMT inhibition and NAD+ precursor availability
- Obesity metabolic programming — NNMT overexpression in obese adipose tissue
- Combination with NAD+ precursors — synergistic preservation and supplementation
- Epigenetic basis of obesity — fat cell gene expression vs genetic predisposition
- Non-appetite-suppressing fat reduction — useful in research designs controlling for hunger
5-Amino-1MQ, NAD+, and semaglutide represent three entirely different approaches to fat reduction — epigenetic, energetic, and appetite-based.
| Aspect | 5-Amino-1MQ | NAD+ / NMN | Semaglutide |
|---|---|---|---|
| Target | NNMT enzyme (adipose) | NAD+/sirtuin pathway | GLP-1 receptor |
| Mechanism | Epigenetic fat cell reprogramming | Energy metabolism restoration | Appetite suppression |
| Appetite Effect | None observed | None | Significant reduction |
| Fat Reduction | Preclinical — without caloric restriction | Indirect (metabolic) | Yes — via deficit |
| Research Stage | Early preclinical | Clinical trials available | FDA approved |
Novel mechanism — epigenetic adipocyte reprogramming not shared by any other research compound
No appetite suppression required — fat reduction without caloric restriction in preclinical models
NAD+ pathway synergy — NNMT inhibition preserves NAD+ precursor pool
Very early stage — compelling concept with initial preclinical data; replication and human studies not yet initiated
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026